EVIO, Inc. (EVIO) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 1.67 means the share price is 1.67 times one year of earnings per share.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerEVIO, Inc. (EVIO) trades at $0.00005. EVIO, Inc. provides analytical testing and advisory services to the cannabis industry in the United States. The company's services include consulting, product formulation, and testing for cannabinoid potency, pesticides, and other contaminants. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for EVIO: EVIO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
EVIO, Inc. (EVIO) Healthcare & Pipeline Overview
EVIO, Inc. provides analytical testing and advisory services to the U.S. cannabis industry, offering consulting, product formulation, and comprehensive testing services. With a focus on cannabinoid potency, pesticide screening, and regulatory compliance, EVIO supports cannabis businesses in navigating the complex landscape of the evolving market.
What Is the Investment Thesis for EVIO?
EVIO, Inc. presents a focused play on the cannabis testing and advisory services market. With a P/E ratio of 1.67 and a gross margin of 33.0%, the company demonstrates potential profitability. Growth catalysts include the expansion of cannabis legalization across states, driving demand for testing and compliance services. Key risks include intense competition and the evolving regulatory landscape. Investors should monitor revenue growth, profitability improvements, and the company's ability to adapt to changing regulations in the cannabis industry.
Based on FMP financials and quantitative analysis
EVIO Key Highlights
EVIO, Inc. operates in the cannabis analytical testing and advisory services market within the United States.
- The company's profit margin is 3.0%, indicating a potential for improvement in operational efficiency.
- EVIO's gross margin stands at 33.0%, reflecting its ability to manage the cost of services effectively.
- The company's P/E ratio is 1.67, suggesting it may be undervalued compared to its earnings.
- EVIO's beta is 81.01, indicating high volatility compared to the market.
Who Are EVIO's Competitors?
EVIO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| APUS Apimeds Pharmaceuticals US, Inc. | $5.03 | +56.21% | $7.59M | — |
| BFRI Biofrontera Inc. | $1.01 | -2.40% | $13.0M | — |
| AKAN Akanda Corp. | $1.98 | -10.41% | — | |
| COSM COSM | $0.38 | -1.58% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.44 | +0.44% | $22.0M | — |
| AYTU Aytu BioPharma, Inc. | $2.07 | -0.96% | $22.2M | — |
| TXMD TherapeuticsMD, Inc. | $2.08 | +1.22% | $24.0M | — |
| CPHI CPHI | $0.67 | +1.57% | $27.0M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EVIO's Key Strengths?
Comprehensive suite of testing and advisory services.
- Expertise in cannabis testing and compliance.
- Established relationships with cannabis businesses.
- Reputation for accuracy and reliability.
What Are EVIO's Weaknesses?
Small size and limited resources.
- Dependence on the cannabis industry.
- Limited geographic reach.
- High beta indicating high volatility.
What Are the Key Risks for EVIO?
Negative return on equity (-0.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Intense competition from other testing labs and consulting firms.
- Evolving regulatory landscape and potential changes in cannabis laws.
- Economic downturn affecting the cannabis industry.
- Limited financial disclosure due to OTC listing.
- Low trading volume and liquidity on the OTC market.
What Are EVIO's Competitive Advantages?
- Specialized expertise in cannabis testing and compliance.
- Established relationships with cannabis businesses.
- Comprehensive suite of testing and advisory services.
- Reputation for accuracy and reliability.
What Does EVIO Do?
EVIO, Inc. was established to provide analytical testing and advisory services to businesses operating within the burgeoning cannabis industry in the United States. Recognizing the need for standardized testing and regulatory compliance in this rapidly evolving market, EVIO has positioned itself as a key service provider for cannabis cultivators, processors, and retailers. The company offers a comprehensive suite of services, including consulting, product formulation, and licensing and compliance assistance. Its analytical testing services encompass cannabinoid potency testing, terpene analysis, pesticide testing, residual solvent screening, visual inspections, and biological contaminant testing. These services are designed to ensure product safety, quality, and compliance with state and local regulations. Headquartered in Henderson, Nevada, EVIO, Inc. aims to support the growth and legitimacy of the cannabis industry by providing reliable and accurate testing and advisory solutions.
What Products and Services Does EVIO Offer?
- Provides analytical testing services to the cannabis industry.
- Offers consulting services related to cannabis product formulation.
- Assists cannabis businesses with licensing and compliance.
- Conducts cannabinoid potency testing.
- Performs terpene analysis.
- Screens for pesticides and residual solvents.
- Conducts visual inspections of cannabis products.
- Tests for biological contaminants.
How Does EVIO Make Money?
- Generates revenue through analytical testing services for cannabis products.
- Earns fees from consulting services related to product formulation and regulatory compliance.
- Partnerships with cannabis cultivators, processors, and retailers.
- Offers specialized testing services, such as heavy metal analysis and genetic testing.
What Industry Does EVIO Operate In?
EVIO, Inc. operates within the rapidly expanding cannabis industry, which is experiencing significant growth due to increasing legalization and acceptance across the United States. The market for cannabis testing and advisory services is becoming increasingly important as regulations tighten and consumers demand safer, more reliable products. Competition is intensifying, with numerous testing labs and consulting firms vying for market share. EVIO's success depends on its ability to maintain high standards of accuracy, compliance, and customer service in this dynamic environment.
Who Are EVIO's Key Customers?
- Cannabis cultivators
- Cannabis processors
- Cannabis retailers
- Cannabis product manufacturers
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
EVIO, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for EVIO, Inc. stands at -0.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.7%, showing how much profit it generates from its asset base. EVIO trades at a trailing price-to-earnings ratio of 1.67, below the Healthcare sector average of ~21.10x. Its free cash flow yield is -37.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.04 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 29.9%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
EVIO, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Henderson, US. The company is led by CEO Lori Jean Glauser. EVIO has traded publicly since 2004.
Insider Activity
9 transactions · 5 purchases, 1 sales, 3 other transactions · 3 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
EVIO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
EVIO Latest News
-
Washington Post Reported President Trump Expected To Announce A Medicare Pilot Program To Reimburse Patients' CBD Treatments
benzinga · Dec 18, 2025
-
'Trump to sign executive order reclassifying marijuana: Officials' -ABC Report
benzinga · Dec 17, 2025
-
Stocks That Hit 52-Week Lows On Tuesday
· Dec 17, 2019
-
Stocks That Hit 52-Week Lows On Friday
· Dec 6, 2019
EVIO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for EVIO.
Price Targets
Wall Street price target analysis for EVIO.
EVIO MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for EVIO; grades run from A+ (80-100) to F (below 30).
Latest News
Washington Post Reported President Trump Expected To Announce A Medicare Pilot Program To Reimburse Patients' CBD Treatments
'Trump to sign executive order reclassifying marijuana: Officials' -ABC Report
Stocks That Hit 52-Week Lows On Tuesday
Stocks That Hit 52-Week Lows On Friday
Leadership: Lori Jean Glauser
CEO
Lori Jean Glauser serves as the CEO of EVIO, Inc. Her background includes experience in managing and growing businesses, with a focus on strategic planning and execution. She has demonstrated leadership in navigating complex regulatory environments and building strong teams. Her expertise is crucial for guiding EVIO through the evolving cannabis industry landscape. She is responsible for overseeing all aspects of the company's operations and driving its growth strategy.
Track Record: Under Lori Jean Glauser's leadership, EVIO, Inc. has focused on expanding its testing and advisory services to meet the growing demand in the cannabis industry. She has overseen the development of new testing capabilities and the expansion of the company's geographic reach. Her strategic decisions have aimed to position EVIO as a trusted partner for cannabis businesses seeking to ensure product safety and regulatory compliance. She manages 18 employees.
EVIO OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that EVIO, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial information available to the public, and trading activity may be sporadic. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure
- Low trading volume and liquidity
- Higher price volatility
- Potential for fraud or manipulation
- Lack of regulatory oversight
- Verify the company's financial statements.
- Research the company's management team and their track record.
- Assess the company's competitive position in the cannabis testing market.
- Review the company's regulatory filings and compliance history.
- Evaluate the company's growth prospects and expansion plans.
- Monitor trading volume and price volatility.
- Consult with a qualified financial advisor.
- Operational testing facilities and advisory services.
- Partnerships with established cannabis businesses.
- Compliance with state and local regulations.
- Positive customer reviews and testimonials.
- Experienced management team.
What Investors Ask About EVIO, Inc. (EVIO) — Healthcare
What do analysts say about EVIO stock?
As of 2026-03-17, formal analyst ratings for EVIO are limited, likely due to its OTC listing and smaller market capitalization. Key valuation metrics include a P/E ratio of 1.67 and a gross margin of 33.0%.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available due to OTC listing.